A Randomized, Controlled, Prospective and Multicenter Clinical Investigation Evaluating the Safety and Performance of ABIO3419 in Treating Knee Osteoarthritis.
Latest Information Update: 04 Mar 2025
At a glance
- Drugs ABIO 3419 (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Sponsors Symatese
Most Recent Events
- 26 Feb 2025 Planned End Date changed from 1 Feb 2026 to 1 Mar 2026.
- 26 Feb 2025 Planned primary completion date changed from 1 Feb 2026 to 1 Sep 2025.
- 26 Feb 2025 Status changed from not yet recruiting to recruiting.